gsk3640254
Showing 1 - 10 of 10
HIV Trial in Austin (GSK3640254, DTG, GSK3640254/DTG)
Completed
- HIV Infections
- GSK3640254
- +2 more
-
Austin, TexasGSK Investigational Site
Sep 21, 2021
HIV Trial in Austin (GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR))
Completed
- HIV Infections
- GSK3640254
- +2 more
-
Austin, TexasGSK Investigational Site
Oct 11, 2021
HIV Trial in Austin (GSK3640254, Placebo, Moxifloxacin)
Completed
- HIV Infections
- GSK3640254
- +2 more
-
Austin, TexasGSK Investigational Site
Nov 16, 2021
Infection, Human Immunodeficiency Virus, HIV Trial in Cambridge (GSK3640254, Placebo)
Completed
- Infection, Human Immunodeficiency Virus
- HIV Infections
- GSK3640254
- Placebo
-
Cambridge, United KingdomGSK Investigational Site
May 28, 2021
HIV Trial in Worldwide (GSK3640254, Dolutegravir, Lamivudine capsules)
Active, not recruiting
- HIV Infections
- GSK3640254
- +3 more
-
Bakersfield, California
- +75 more
Jul 1, 2022
HIV Trial in Worldwide (GSK3640254, ABC/3TC, FTC/TAF)
Active, not recruiting
- HIV Infections
- GSK3640254
- +4 more
-
Los Angeles, California
- +65 more
Jul 18, 2022
HIV Trial in Worldwide (GSK3640254, Placebo matching GSK3640254 Mesylate salt)
Completed
- HIV Infections
- GSK3640254
- Placebo matching GSK3640254 Mesylate salt
-
Bakersfield, California
- +22 more
Jan 27, 2021
HIV Trial in Austin (GSK3640254, Portia)
HIV Trial in Austin (Tenofovir alafenamide/emtricitabine, GSK3640254)
Completed
- HIV Infections
- Tenofovir alafenamide/emtricitabine
- GSK3640254
-
Austin, TexasGSK Investigational Site
Apr 7, 2020